Live

Tariff updates: Trump escalates threats on China as markets remain jittery

NasdaqCM - Nasdaq Real Time Price USD

CytoMed Therapeutics Limited (GDTC)

2.3250

-0.0450

(-1.90%)

As of 11:53:25 AM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for GDTC

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India

CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India

CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India

CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India

Sector Update: Health Care Stocks Edge Higher Premarket Monday

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

CytoMed Therapeutics Leads 3 US Penny Stocks To Consider

CytoMed Therapeutics Leads 3 US Penny Stocks To Consider

CytoMed Therapeutics And 2 Other US Penny Stocks To Watch

CytoMed Therapeutics And 2 Other US Penny Stocks To Watch

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CSBR Champions Oncology, Inc.

8.05

+7.48%

NBY NovaBay Pharmaceuticals, Inc.

0.4901

-5.17%

COEPW Coeptis Therapeutics Holdings, Inc.

0.0078

-17.02%

COEP Coeptis Therapeutics Holdings, Inc.

9.25

-4.34%

SXTP 60 Degrees Pharmaceuticals, Inc.

1.7400

-1.14%

ONPH Oncology Pharma Inc.

0.0001

0.00%

KTTA Pasithea Therapeutics Corp.

1.2200

-3.94%

CHRO Channel Therapeutics Corporation

1.3100

-3.94%

INTS Intensity Therapeutics, Inc.

1.8901

+1.07%

IMRN Immuron Limited

1.7650

+0.28%